Nordic Capital is to acquires a majority share in IntegriChain, a provider of pharmaceutical technology, data, consulting, and outsourcing solutions designed to improve how life sciences products reach customers.
IntegriChain delivers ICyte, a fully integrated platform for commercialisation and market access, helping manufacturers bring their science to market while ensuring patients have affordable, timely, and sustainable access to therapy.
Nordic Capital is acquiring the majority stake from Accel-KKR, a global software private equity firm, which first invested in IntegriChain in 2016.
Terms of the transaction, which is expected to complete before the end of the year subject to customary closing conditions, have not been disclosed.
